Medical Aspects of Chemical Warfare (2008) - The Black Vault

More documents

Recommendations

Info

Incapacitating Agents87. Chen Y, Dalwadi G, Benson HA. Drug delivery across the blood-brain barrier. Curr Drug Deliv. 2004;1:361–376.88. US Department of the Army. Army Science and Technology Master Plan, March 1997. Fort Sam Houston, Tex: US ArmyMedical Center and School; 1998: Chap 5.89. Ketchum JS, Sidell FR, Crowell EB, Aghajanian GK, Hayes AH. Atropine, scopolamine, and ditran: comparativepharmacology and antagonists in man. Psychopharmacology (Berlin) 1973;28:121–145.90. Wolff HG, Curran D. Nature of delirium and allied states: dysergastic reaction. Arch Neurol Psychiatr. 1935;33:1175–1215.91. Waelbroeck M, Taskenoy M, Camus J, Christophe J. Binding kinetics of quinuclidinyl benzilate and methyl- quinuclidinylbenzilate evantiomers at neuronal (M1), cardiac (M2), and pancreatic (M3) muscarinic receptors. Mol Pharmacol.1991;40:413–420.92. Hayes AH, Copelan H, Ketchum JS. The effect of high intramuscular doses of atropine sulfate on the human electrocardiogram.Clin Pharmacol Ther. 1971;12:482–486.93. Ketchum JS. The Human Assessment of BZ. Edgewood Arsenal, Md: Chemical Research and Development Laboratory;1963. Technical Memorandum 20-29.94. Zvirblis P, Kondritzer A. Adsorption of H3BZ and C14-Atropine to the Mitochondrial Fraction of the Rat Brain. EdgewoodArsenal, Md: Chemical Research and Development Laboratory; 1966. Edgewood Arsenal Technical Report 4042.95. Moran LJ, Mefferd RB. Repetitive psychometric measures. Psychol Rep. 1959;3:209–275.96. Biel JH, Nuhfer PA, Hoya WK, Leiser HA, Abood LG. Cholinergic blockade as an approach to the development ofnew psychotropic agents. Ann NY Acad Sci. 1962;96:251–262.97. Abood, LG. Structure-activity relations of the centrally active anticholinergic agents. In: National Academies of Science,Commission on Life Sciences. Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents. Vol 1.Washington, DC: National Academy Press;. 1982: 275–284.98. Forrer GR. Atropine toxicity in the treatment of schizophrenia. J Michigan State Med Soc. 1950;49:184–185.99. Miller JJ, Schwarz H, Forrer GR. Atropine coma therapy. Paper presented at: Michigan State Medical Society meeting,1957.100. Wada T, Horigome S, Sakurada T. Clinical experience of the so-called “atropine toxicity therapy [Forrer].” Tohoku JExp Med. 1960;72:398–404.101. Kitzes DL, Ketchum JS. Estimate of Minimal Effective Dose of EA 3443 in Man. Edgewood Arsenal, Md: Chemical Researchand Development Laboratory; 1965. CRDL Technical Memorandum 2-29.102. Crowell EB, Jr. EA 3580A: Estimate of Incapacitating Dose in Man. Edgewood Arsenal, Md: Chemical Research andDevelopment Laboratory; 1965. CRDL Technical Memorandum 2-20.103. Aghajanian GK, Kitzes DL, Harper DG, Bottiglieri NG. EA 3580A: Estimate of Minimal Effective Dose In Man. EdgewoodArsenal, Md: Chemical Research and Development Laboratory; 1965. CRDL Technical Memorandum 2-12.104. Kitzes DL, Ketchum JS, Weimer JT, Farrand RL. The Human Assessment of EA 3580 by the Aerosol Route. EdgewoodArsenal, Md: Chemical Research and Development Laboratory; 1967. Edgewood Arsenal Technical Report 4041.105. Sidell FR, Ketchum JS, Markis JE, Kysor KP. Compound 302,196: Intramuscular Administration to Man. Edgewood Arsenal,Md: Chemical Research and Development Laboratory; 1972. Edgewood Arsenal Technical Report No. 4634.106. Tharp BR, Mershon M, Bottiglieri N. Estimate of Intravenous MED50 of CS 27349 (219,758). Edgewood Arsenal, Md:Chemical Research and Development Laboratory; 1964. Edgewood Arsenal Task Plan 7010.437
Medical Aspects of Chemical Warfare107. Copeland HW. MED50 of Agent 3834. Final Report, Contract No. DAAA15-68-C 0627. Edgewood Arsenal, Md: ChemicalResearch and Development Laboratory; 1968.108. Sidell FR, Braun BG. EA 3834A: Effects in Man After a Single Oral Dose. Edgewood Arsenal, Md: Chemical Researchand Development Laboratory; 1972. Edgewood Arsenal Technical Report 4597.109. McCarroll E, Markis J, Ketchum JS, Houff W, Sim VM. Effects on Performance of the Administration of EA 3834 to Membersof a Small Infantry Element Under Simulated Combat Conditions. Edgewood Arsenal, Md: Chemical Research andDevelopment Laboratory; 1971. Edgewood Arsenal Technical Report 4633.110. Ketchum JS, Kitzes D, Copelan H. EA 3167: Effects In Man. Edgewood Arsenal, Md: Chemical Research and DevelopmentLaboratory; 1973. Edgewood Arsenal Technical Report 4713.111. Hayes AH, Copelan H. Intramuscular MED50 of 302668. Edgewood Arsenal, Md: Chemical Research and DevelopmentLaboratory; 1967. Edgewood Arsenal Contract DA-18-035-AMC-126.112. Copelan HW. MED50 of Agent 302282. Edgewood Arsenal, Md: Chemical Research and Development Laboratory;1967.Contract No. DA-18-035-AMC-126 (A) Report No. IV.113. Arthur D Little Inc, Sterling Winthrop Research Institute. Preclinical Pharmacology and Toxicology of Candidate Agent226086. Edgewood Arsenal, Md: Chemical Research and Development Laboratory; 1966. Contract No. EA 18-108-AMC-103(A) Quarterly Report 1.114. Hayes AH, Copelan H. Intramuscular MED50 of 302668 (Addendum). Edgewood Arsenal, Md: Chemical Research andDevelopment Laboratory; 1967. Contract No. DA-18-035-AMC-126 (A).115. Sidell FR, Ketchum JS, Markis JE, Kysor KP. Compound 302,196: Intramuscular Administration to Man. Edgewood Arsenal,Md: Chemical Research and Development Laboratory;1972. Edgewood Arsenal Technical Report No. 4634.116. Federation of American Scientists. Using toxic properties of chemical substances. Adapted from Militarily CriticalTechnologies List Part II: Weapons of Mass Destruction Technologies. FAS Web site. Available at: http://www.fas.org/nuke/intro/cw/intro.htmsing. Accessed November 17, 2005.117. Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 3rd ed. New York, NY: Macmillan; 1965:521–545.118. Crowell EB, Ketchum JS. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther.1967;8:409–414.119. Kleinwachter I. Observations concerning the effectiveness of extract of Calabar against atropine poisoning. Berl KlinWschr. 1864;1:369–377.120. Sidell FR, Aghajanian GK, Groff WA, Cucinell SA. The reversal of anticholinergic intoxication in man with the cholinesteraseinhibitor VX. Proc Soc Exp Biol Med. 1973;144:725–730.121. Sidell FR, Groff WA. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol.1974:27:241–252.122. Gershon S. Blocking effect of tetrahydroaminacrin on a new psychotomimetic agent. Nature. 1960;186:1072–1073.123. Bell C, Gershon S, Carroll B, Holan G. Behavioural antagonism to a new psychotomimetic: JB-329. Arch Intern PharmacodynTher. 1964;147:9–25.124. Ostfeld AM, Visotsky H, Lebonits B. A comparison of the psychotomimetic effects of scopolamine, LSD and n-ethyl-3-piperidyl benzilate (JB 318). Clin Res. 1958;6:416.125. Duvoisin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostigmine. JAMA. 1968;206:1963–1965.438
Page 3 and 4:
The Coat of Arms1818Medical Departm
Page 5:
Textbooks of Military MedicinePubli
Page 8 and 9:
MEDICAL ASPECTS o fCHEMICAL WARFARE
Page 10 and 11:
ContentsContributorsForeword by The
Page 12 and 13:
ContributorsMICHAEL ADLER, PhDResea
Page 14 and 15:
DONALD M. MAXWELL, MSResearch Chemi
Page 16 and 17:
ForewordThe US military has been co
Page 18 and 19:
PrefaceA significant concern for th
Page 20:
PrologueThe original edition of Med
Page 23 and 24:
xxii
Page 25 and 26:
Medical Aspects of Chemical Warfare
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 178 and 179:
Nerve AgentsChapter 5NERVE AGENTSFR
Page 180 and 181:
Nerve AgentsAbout 10,000 to 30,000
Page 182 and 183:
Nerve Agentsphorofluoridate (DFP) w
Page 184 and 185:
Nerve AgentsFig. 5-2. This schemati
Page 186 and 187:
Nerve AgentsExhibit 5-1 continuedis
Page 188 and 189:
Nerve Agentsactivity but only 15% t
Page 190 and 191:
Nerve AgentsTABLE 5-3CHEMICAL, PHYS
Page 192 and 193:
Nerve AgentsTABLE 5-4EFFECTS OF EXP
Page 194 and 195:
Nerve Agentsaffecting the other eye
Page 196 and 197:
Nerve Agentsmay cause severe rhinor
Page 198 and 199:
Nerve Agentsof jerks and tremor.Cen
Page 200 and 201:
Nerve Agentsand they were decreased
Page 202 and 203:
Nerve Agentsnerve agent toxicity on
Page 204 and 205:
Nerve Agentspatient. Decontaminatio
Page 206 and 207:
Nerve AgentsFig. 5-5. The Mark I ki
Page 208 and 209:
Nerve Agentsadministered intramuscu
Page 210 and 211:
Nerve Agentsthat hydroxamine reacti
Page 212 and 213:
Nerve AgentsOral administration may
Page 214 and 215:
Nerve AgentsTABLE 5-7RECOMMENDED TH
Page 216 and 217:
Nerve Agentsimpairment such as whee
Page 218 and 219:
Nerve Agentssuboptimal, manner. The
Page 220 and 221:
Nerve Agentsthan those who did not.
Page 222 and 223:
Nerve Agentssible for binding nerve
Page 224 and 225:
Nerve Agentsfor comparison was not
Page 226 and 227:
Nerve AgentsTABLE 5-11EFFECTS OF PY
Page 228 and 229:
Nerve Agentstivity of smooth muscle
Page 230 and 231:
Nerve Agents38. Grob D, Lilienthal
Page 232 and 233:
Nerve Agents77. McDonough JH, Shih
Page 234 and 235:
Nerve Agents117. McLeod CG Jr, Sing
Page 236 and 237:
Nerve Agents154. Tryphonas l, Veino
Page 238 and 239:
Nerve Agents193. Funckes AJ. Treatm
Page 240 and 241:
Nerve Agents235. Suzuki T, Morita H
Page 242:
Nerve Agents274. Pellegrini JE, Bak
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
PROCESSMedical Aspects of Chemical
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410: Medical Aspects of Chemical Warfare
Page 459: Medical Aspects of Chemical Warfare
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 534 and 535:
Triage of Chemical CasualtiesChapte
Page 536 and 537:
Triage of Chemical Casualtiesreceiv
Page 538 and 539:
Triage of Chemical Casualtiesentran
Page 540 and 541:
Triage of Chemical Casualtiescatego
Page 542 and 543:
Triage of Chemical CasualtiesIn a f
Page 544 and 545:
Triage of Chemical Casualtiesnose)
Page 546 and 547:
Triage of Chemical CasualtiesWith n
Page 548 and 549:
Triage of Chemical Casualties14. Sa
Page 550 and 551:
Decontamination of Chemical Casualt
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
Page 607 and 608:
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
Page 615 and 616:
Page 617 and 618:
Page 619 and 620:
Page 621 and 622:
Page 623 and 624:
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Page 637 and 638:
Page 639 and 640:
Page 641 and 642:
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
Page 651 and 652:
Page 653 and 654:
Page 655 and 656:
Page 657 and 658:
Page 659 and 660:
Page 661 and 662:
Page 663 and 664:
Page 665 and 666:
Page 667 and 668:
Page 669 and 670:
Page 671 and 672:
Page 673 and 674:
Page 675 and 676:
Page 677 and 678:
Page 679 and 680:
Page 681 and 682:
Page 683 and 684:
Page 685 and 686:
Page 687 and 688:
Page 689 and 690:
Page 691 and 692:
Page 693 and 694:
Page 695 and 696:
Page 697 and 698:
Page 699 and 700:
Page 701 and 702:
Page 703 and 704:
Page 705 and 706:
Page 707 and 708:
Page 709 and 710:
Page 711 and 712:
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
Page 719 and 720:
Page 721 and 722:
Page 723 and 724:
Page 725 and 726:
Page 727 and 728:
Page 729 and 730:
Page 731 and 732:
Page 733 and 734:
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Page 741 and 742:
Page 743 and 744:
Page 745 and 746:
Page 747 and 748:
• Analyze using GC-MS with methan
Page 749 and 750:
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
Page 757 and 758:
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
Page 765 and 766:
Page 767 and 768:
Page 769 and 770:
Page 771 and 772:
Page 773 and 774:
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
Page 781 and 782:
Page 783 and 784:
Page 785 and 786:
Page 787 and 788:
Page 789 and 790:
Page 791 and 792:
Page 793 and 794:
Page 795 and 796:
Page 798 and 799:
Abbreviations and AcronymsAbBreviat
Page 800:
Abbreviations and AcronymsPADPRP: p
Page 803 and 804:
Page 805 and 806:
Page 807 and 808:
Page 809 and 810:
Page 811 and 812:
Page 813 and 814:
Page 815 and 816:
Page 817 and 818:
Page 819 and 820:
Page 821 and 822:
Page 823 and 824:
Page 825 and 826:
Page 827 and 828:
Page 829 and 830:
Page 831 and 832:
Page 833 and 834:
Page 835 and 836:
Page 837 and 838:
Page 839 and 840:
Page 841 and 842:
Page 843 and 844:
Page 845:
show all

Medical Aspects of Chemical Warfare (2008) - The Black Vault

Create successful ePaper yourself

Delete template?

Save as template?